Immunological and gene therapy for ovarian cancer a technical overview.
Conventional medical approaches are limited in part on the prognosis of ovarian cancer. Although the advent of platinum- and taxane-based combination chemotherapy represents a significant advance in the treatment of ovarian carcinoma, the 5-yr survival of patients with intraperitoneal (ip) disseminated disease remains poor at only 30-40% (1-3). The vast majority of patients present with disease that is advanced because of transcoelomic spread yet remains locoregionally contained, rather than truly metastatic to distant sites by blood or lymphatic spread.